Podcasts about pacific biosciences

Join me and Dr. Colleen Cutcliffe, my brilliant friend, scientist, and the powerhouse CEO of Pendulum, for our deepest dive yet into all things Akkermansia. This free-flowing conversation will take your understanding of this extraordinary strain to a whole new level. We'll explore Akkermansia's pivotal role in metabolic health—think cravings, weight regulation, A1C—and why we're deficient in the first place. Plus, we'll discuss its connection to stress, anxiety, and even neurodegenerative diseases. We'll also dive into the hotly debated topic of Akkermansia's impact on MS, unpacking both sides of the controversy. And, we'll touch on its promising influence on hormonal balance, from infertility to menopause. As someone who's deeply invested in science, I'm personally bullish on Akkermansia and trust Pendulum's products as part of my own foundational health stack. With groundbreaking science and fresh insights, this episode will change the way you approach your practice. ~DrKF Check out the show notes at https://www.drkarafitzgerald.com/fxmed-podcast/ for the full list of links and resources. GUEST DETAILS Colleen Cutcliffe, PhD, Co-Founder and CEO of Pendulum Therapeutics Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. She has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern's Children's Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College. THANKS TO OUR SPONSOR Pendulum: https://tinyurl.com/hzbxh75f EXCLUSIVE OFFER FOR NEW FRONTIERS LISTENERS Healthcare providers - Create a healthcare account with Pendulum to unlock wholesale pricing and get $50 off your first wholesale order with code WSKARA50 at https://tinyurl.com/hzbxh75f Not a practitioner but ready to try Pendulum probiotics for yourself? Take 20% off your first membership order with code KARA20 at checkout. https://tinyurl.com/2tjp3jb4 CONNECT WITH DrKF Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You Group Program: https://tinyurl.com/4hvusavw Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

Colleen Cutcliffe explores the microbiome's role during menopause, focusing on the estrobolome and gut bacteria's interaction with estrogen. She emphasizes the importance of gut health, particularly Acromantia, and discusses the negative impacts of birth control pills and antibiotics. Along with Dr. Mindy, they highlight essential microbes, dietary changes, and probiotics for wellness, and examine the long-term effects of weight loss drugs on the microbiome. Lastly, they stress measuring health through energy levels and the four pillars of well-being: nutrition, exercise, mental health, and the microbiome. To view full show notes, more information on our guests, resources mentioned in the episode, discount codes, transcripts, and more, visit https://drmindypelz.com/ep271 Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. She has more than 15 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern's Children's Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College. Check out our fasting membership at resetacademy.drmindypelz.com. Please note our medical disclaimer.

Curious about the connection between your gut, brain and blood glucose?Joining Krista on Almost 30 today is Colleen Cutcliffe, co-founder and Chief Executive Officer of Pendulum. In this episode, you'll learn about the probiotics industry and why Pendulum products are an effective solution in managing your gut health.Colleen has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. She is truly a wealth of knowledge and we're so excited for #Almost30Nation to learn more about their gut microbiome!Morning Microdose is a podcast curated by Krista Williams and Lindsey Simcik, the hosts and founders of Almost 30, a global community, brand, and top rated podcast.With curated clips from the Almost 30 podcast, Morning Mircodose will set the tone for your day, so you can feel inspired through thought provoking conversations…all in digestible episodes that are less than 10 minutes.Wake up with Krista and Lindsey, both literally and spiritually, Monday-Friday.If you enjoyed this conversation, listen to the full episode on Spotify here and on Apple here.

In this enlightening session, Dr. Jill Carnahan dives deep into the cutting-edge world of probiotics and the game-changing "Un-Hunger Hormone" with none other than biotech pioneer, Colleen Cutliffe, PHD. Join us as we explore the revolutionary GLP-1 Probiotic, a groundbreaking innovation that promises to boost GLP-1 production and transform metabolic health. Colleen Cutliffe, PHD, CEO and co-founder of Pendulum, shares her expertise on how this unique probiotic can effectively manage hunger, improve gut health, and support overall wellness.

Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. She has more than 15 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern's Children's Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.   https://pendulumlife.com/   If you are a healthcare provider, access provider education at wholesale pricing HERE.

This weeks guest is Dr. Colleen Cutcliffe. Dr. Colleen Cutcliffe is a researcher and a thinker with persistence. Throughout history, these are the human qualities that lead people to develop amazing products and lead projects for the world to benefit from. Her story is one of discovery, passion and caring. Dr. Cutcliffe holds a Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and a B.A. in Biochemistry from Wellesley College. Her scientific background is complemented by her experience in managing both research and operations teams in the biotech sector. Before founding Pendulum Therapeutics, she held senior positions at Pacific Biosciences and Elan Pharmaceuticals, where she was instrumental in developing various technological platforms. She is the co-founder and CEO of Pendulum Therapeutics, a biotechnology company focused on developing innovative solutions to improve gut health through microbiome-based interventions. With over 20 years of experience in the biotechnology industry, Dr. Cutcliffe has become a recognized leader in microbiome science, applying her expertise to bridge the gap between cutting-edge research and practical, consumer-facing health solutions. At Pendulum Therapeutics, Dr. Cutcliffe has led the development of novel probiotic formulations specifically designed to address metabolic diseases like type 2 diabetes. Her work has been pivotal in the growing recognition of the microbiome's role in human health, pushing forward the concept of targeted probiotics as a potential therapeutic option. Under her leadership, Pendulum Therapeutics has gained recognition for its scientific rigor and innovative approaches to personalized nutrition. Today, we discuss the story of her discovery and the fact that her work is the beginning of a hopeful wave of change for humans through gut microbiome manipulation. Dr. Cutcliffe helps us understand the basics of the microbiome, what helps it stay balanced and conversely, what upsets it. How does it support our metabolism and health in general. The main thrust of her work comes into the spotlight with Akkermansia mucinophilia, a keystone species for positive health. Please Enjoy my conversation with Dr. Cutcliffe, Dr. M

I am delighted to have Dr. Colleen Cutcliffe, the CEO and Co-founder of Pendulum, joining me today.  Dr. Cutcliffe is a proud alumnus of Johns Hopkins, with over 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotech. Before starting Pendulum, she was the Senior Manager of Biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals.  In our discussion today, we dive into the emerging science of the gut microbiome, examining the effects of aging, antibiotics, nutrition, stress, travel, and menopause on gut health and discussing how vaginal and C-section deliveries differ in impact. We explore differentiators for various categories of bacteria and the roles of butyrate and fiber, looking at fecal transplants and the difference between probiotics, prebiotics, and post-biotics, and explaining why Akkermansia is an essential bacteria for regulating insulin satiety, fortifying the mucin layer, and facilitating targeted delivery of butyrate. Dr. Cutcliffe also shares her top tips for mitigating the effects of travel on the gut microbiome and offers a special discount for listeners.  I am confident that you will find today's discussion with Dr. Colleen Cutcliffe engaging and enlightening. Stay tuned to learn how to adjust your lifestyle for a healthier gut microbiome. IN THIS EPISODE YOU WILL LEARN: The benefits of a vaginal delivery Various factors that disrupt the gut microbiome Why it is essential to get enough fiber in your diet What are the signs and symptoms of an unhealthy gut microbiome? The benefits of fecal transplants How the vagus nerve fosters communication between the gut and brain Why artificial sweeteners might not be as harmful to the gut microbiome as previously thought How prebiotics, probiotics, and postbiotics are interconnected and necessary for overall health The role of Akkermansia in the gut microbiome How to maintain a healthy gut microbiome while traveling   Bio: Dr. Colleen Cutcliffe: Colleen Cutcliffe, PhD, is the CEO and Co-Founder of Pendulum. She has over 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Before starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College. Connect with Cynthia Thurlow Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Colleen Cutcliffe On the Pendulum Life website Use code THURLOW for 20% off your first order of Pendulum products.

Curious about the connection between your gut, brain and blood glucose?Joining Krista on Almost 30 today is Colleen Cutcliffe, co-founder and Chief Executive Officer of Pendulum. In this episode, you'll learn about the probiotics industry and why Pendulum products are an effective solution in managing your gut health.Colleen has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. She is truly a wealth of knowledge and we're so excited for #Almost30Nation to learn more about their gut microbiome!Morning Microdose is a podcast curated by Krista Williams and Lindsey Simcik, the hosts and founders of Almost 30, a global community, brand, and top rated podcast.With curated clips from the Almost 30 podcast, Morning Mircodose will set the tone for your day, so you can feel inspired through thought provoking conversations…all in digestible episodes that are less than 10 minutes.Wake up with Krista and Lindsey, both literally and spiritually, Monday-Friday.If you enjoyed this conversation, listen to the full episode on Spotify here and on Apple here.

Pacific Biosciences of California, Inc. v. Personal Genomics Taiwan, I

You might've heard me say it before: "The gut is the second brain." With over two decades of leadership in biotech, pharma, and academia, my guest on today's show, Colleen Cutliffe, is gut-deep :) in microbiome knowledge. Her path, spanning from the hallowed halls of Johns Hopkins University to groundbreaking initiatives at Pacific Biosciences and Elan Pharmaceuticals, showcases an unyielding curiosity about the mysteries of the human body. Now, as the driving force behind Pendulum Therapeutics, Colleen is charting new territories in the world of the microbiome. Akkermansia muciniphila, one of Pendulum's products, is a unique oval-shaped bacterium that thrives in the human gastrointestinal tract. This anaerobic microbe predominantly resides at the junction between oxygen-rich and oxygen-depleted zones of the intestines. Found in about 90% of healthy individuals, it constitutes 1% to 3% of your fecal microbiota. However, its prevalence can decrease with age or certain diseases. In today's chat, Colleen unravels the enigma of the gut-brain axis and its monumental influence on the microbiome's functionality. She sheds light on the role of natural agents like berberine, bitter melon extract, apple cider vinegar, and even pharmaceuticals like metformin in regulating blood sugar. With insights into the importance of Akkermansia muciniphila in GLP-1 production and the captivating genetic variations within the microbiome, this conversation promises a comprehensive look at gut health like never before. Full show notes: https://bengreenfieldlife.com/pendulumpodcast Episode Sponsors: JoyMode: Want to spice things up in the bedroom and boost your sexual performance? Visit usejoymode.com/GREENFIELD or enter GREENFIELD at checkout for 20% off your first order. Hiya: Get your kids the full-body nourishment they need to grow into healthy adults. Visit hiyahealth.com/BEN for 50% off your first order. Pendulum: Metabolic Daily is a powerful multi-strain probiotic that improves your metabolism, reduces sugar cravings, and breaks down carbs more efficiently. 20% off your first month with code GREENFIELD PendulumLife.com/Greenfield. Beam Minerals: If you want to up your mineral game, give Beam Minerals a try. Go to beamminerals.com and use code BEN at checkout for 20% off your order. FUM: Stopping is something we all put off because it's hard, but switching to Füm is easy, enjoyable, and even fun. Visit tryfum.com/BEN and use code BEN for 10% off your order.See omnystudio.com/listener for privacy information.

In this episode of Habits and Hustle, I chat with Colleen Cutcliffe who gives us a step-by-step guide on all things gut health – understanding why optimization is key, why it's growing in popularity, how your gut is controlling you, and exactly what you should do to reclaim your gut microbiome. We also dive into how the gut is linked to your metabolism, the popular trend of glucose control and why we should be concerned about our glucose levels, and why an increasing number of people are seeking natural alternatives to metformin. Colleen Cutcliffe is the CEO and Co-Founder of Pendulum Therapeutics. Colleen has over 20 years of experience managing and leading teams in biotech, pharma, and academia. Before starting Pendulum Therapeutics, Colleen served as the Senior Manager of Biology at Pacific Biosciences, which is where she met her two co-founders. Prior to that, Colleen was a Scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral research at Northwestern's Children's Memorial Hospital, received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and received her B.A. in Biochemistry from Wellesley College. Use code “JENCOHEN” for 20% off of your first bottle of membership at pendulumlife.com What we discuss: (0:09:01) - Akkermansia's Role in Gut Health (0:17:41) - GLP-1 and Akkermansia in Metabolism (0:31:36) - Longevity Drugs and Glucose Control (0:35:01) - Glucose Control and Metabolic Supplement Benefits (0:45:16) - Gut Health Benefits and Quality Control (0:57:15) - Understanding Acromantia and Its Benefits Thank you to our sponsors: Pendulum: Head over to www.pendulumlife.com and use code JENCOHEN for 20% off. Therasage: Head over to therasage.com and use code Be Bold for 15% off Ketone IQ (HVMN): You can save 30% off your first subscription order of Ketone-IQ at HVMN.com/JEN Find more from Jen:  Website: https://www.jennifercohen.com/ Instagram: @therealjencohen  Books: https://www.jennifercohen.com/books Speaking: https://www.jennifercohen.com/speaking-engagement Learn more from Colleen Cutcliffe: Website: https://pendulumlife.com/ Instagram: https://www.instagram.com/pendulumlifeco/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Curious about the connection between your gut, brain and blood glucose? Joining Krista on Almost 30 today is Colleen Cutcliffe, co-founder and Chief Executive Officer of Pendulum. In this episode, you'll learn about the probiotics industry and why Pendulum products are an effective solution in managing your gut health.  Colleen has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. She is truly a wealth of knowledge and we're so excited for #Almost30Nation to learn more about their gut microbiome!  Head to Pendulumlife.com and use code ALMOST30 to save 20% on your first month of any Pendulum product membership.  We also talk about: Societal perception of probiotics What is akkermansia Symptoms of GI distress The connection between your blood glucose + gut Understanding GLP-1 How the microbiome impacts your metabolism  The impact of genetics vs. lifestyle on your gut microbiome How to support your gut microbiome The connection between your gut + brain Resources:  Website: pendulumlife.com Colleen's LinkedIn Pendulum LinkedIn Instagram: @pendulumlifeco Twitter: @Pendulum_Co Amazon Storefront: Pendulum Sponsors: IQ Bar | Get 20% off all IQBAR products by texting ALMOST to 64000.  AG1 | If you want to take ownership of your health, try AG1 and get a FREE 1-year supply of Vitamin D AND 5 Free AG1 Travel Packs with your first purchase. Go to drinkAG1.com/ALMOST30.  Osea | Head to OSEAMalibu.com and get 10% off your first order sitewide with code APOD30.  Catori Life | Get a 20% discount with any purchase at catorilife.com. SKIMS | SKIMS Fits Everybody and more best-selling essentials are available now at SKIMS.com. Plus, get free shipping on orders over $75.  To advertise on our podcast, please reach out to sales@advertisecast.com or visit https://www.advertisecast.com/Almost30.  Learn More: almost30.com/learn almost30.com/morningmicrodose almost30.com/courses  Join our community: almost30.com/membership facebook.com/Almost30podcast/groups Podcast disclaimer can be found by visiting: almost30.com/disclaimer.  Find more to love at almost30.com! Almost 30 is edited by Marielle Marlys.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Here we discuss how to measure your gut microbiome, what the future of probiotic and gut microbiome research may hold and what Dr Cutcliffe's personal regimen is.

Metabolic Daily is a less potent but more available form of the Glucose Control probiotic used in the clinical trial. Dr Colleen Cutcliffe discusses the differences in the formulations, the best time to take and what effects people have seen

We talk to Dr Colleen Cutcliffe about a clinical trial that they ran with 5 strains of probiotic. We also talk about whether the strains remained resident and what are the best prebiotics for akkermansia.

We talk to Dr Colleen Cutcliffe about akkermansia muciniphila a probiotic that is involved in Some links are affiliate links so we will earn a commission when they are used to purchase products.

US futures are pointing to a lower open after climbing slightly higher in afterhours. European equity markets have also opened negative, following lower levels in Asia. Fallout continues from Fitch's downgrading of US credit rating. Downgrade blamed in part for risk-off move in equities though sell-side firms downplayed significance for Treasuries.Companies Mentioned: Hasbro, Lions Gate Entertainment, Pacific Biosciences

In this episode of One day with Jon Bier, Jon talks with Colleen Cutcliffe to break down the complexities of microbiome science. Listen in as Colleen highlights the importance of replenishing and maintaining a thriving gut microbiome in a modern society that overlooks its role as a cornerstone of health and wellness. She discusses the importance of the bacterium Akkermansia and why its regulation is key to gut health. Finally, Colleen discusses signs to look for which indicate a recovering microbiome, and how to ensure that recovery following chemo or taking an antibiotic. Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. Colleen has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to co-founding Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Powerful Quotes by Colleen There are so many diseases that are associated with the depletion of Akkermansia that it's emerging as this keystone strain that you simply have to have. After you take an antibiotic, your microbiome is in its most vulnerable state. You have a blank slate, and what you decide to feed it now can make or break the playing field. Key Highlights A healthy microbiome “covers” us in bacteria, viruses, and fungi in order to be protected from allergens that are always present in our environment. Because of our modern focus on scrubbing ourselves clean of these bacteria, those allergens have the opportunity to directly interact with our immune system. This is why we're experiencing an increase in allergies, asthma, immune and autoimmune responses. Multiple studies, including one by Mayo Clinic, reveal that children who are consistently on antibiotics are systematically more prone to obesity, diabetes, celiac disease, allergies, ADHD, etc. This is all due to their microbiome being unable to recover from the prolonged administration of antibiotics. The microbiomes of the healthiest people are composed of 3-5% Akkermansia, which is a huge number for a single strain. Episode resources: Go to getneuro.com and use code “ONEDAY” at checkout for 15% off your entire order! Connect with Colleen Cutcliffe LinkedIn: Colleen Cutcliffe Connect with Jon Bier Instagram: @jonbier13 Twitter: @jonbier13 Facebook: @jonbier13

#sponsoredepisodeDid you realize how much your gut microbiome influences your metabolism, your weight and your overall health? Dr. Whitney talks with Colleen Cutcliffe, PhD, CEO and Co-Founder of Pendulum Therapeutics about how the gut microbiome works, optimizing the way your body handles the nutrients you consume, and choosing a probiotic that really works. Colleen Cutcliffe, PhD, is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.You can find out more at www.modernmommydoc.com/podcastAbout Pendulum:Pendulum optimizes the metabolism of sugar and carbohydrates, reducing sugar cravings and energy slumps, boosting sugar and carb metabolism, AND supporting a healthy weight. Pendulum understands that whole-body health and wellness is tied to the complex ecosystem of microorganisms that is the microbiome, and that addressing imbalances in the microbiome transform people's lives from the inside.Their mission is simple: to improve the lives of millions through microbiome products. To that end, they create products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic.To accomplish their mission, they developed an entirely new product–a medical probiotic. Medical probiotics are the bridge between nature and medicine, helping restore our bodies to their peak balance.To learn more about Pendulum Therapeutics AND to get 20% off your first month of Pendulum membership, go to www.pendulumlife.com and use code MODERN20

When scientists want to know about genes, chances are they use instruments called sequencers. There are quite a few companies that make sequencers. These instruments can give a read-out for example of a stretch of DNA or many stretches of DNA, even entire genomes and many genomes. The challenge has been that the instruments deliver--short reads—short readouts of sequence. What happens then is that scientists face the challenging computational task of stitching together short reads into contiguous sequence. But long-read sequencing is a way to address this challenge. The method of the year according to Nature Methods is: long read-sequencing. For a story I chatted with scientists at companies and in academia about long-read sequencing. This episode is with Dr. Jonas Korlach, chief scientific officer of Pacific Biosciences, which is one of the companies that offers instruments that can do long-read sequencing. (Art: J. Jackson. The following music was used for this media project:Music:  Winnie the Moog, Funky Energetic Intro and Acid Trumpet by Kevin MacLeod Free download: https://filmmusic.io/song/3340-acid-trumpet License (CC BY 4.0): https://filmmusic.io/standard-license0 

This week's conversation is with Dr. Colleen Cutcliffe, the CEO and Co-Founder of Pendulum Therapeutics.Colleen's extensive background includes a doctorate in Biochemistry and Molecular Biology from Johns Hopkins University, and over 20 years of experience managing and leading teams in biotech, pharma, and academia.In 2013, Colleen left her position as Senior Manager of Biology at Pacific Biosciences to start Pendulum, a company on a mission to improve health through first of its kind research and development in the gut microbiome.Pendulum's next generation probiotics are pioneering ways for people to transform their health and wellness by unlocking the power of the gut microbiome.I've been studying gut health and the microbiome for a long time now, and it's clear that Pendulum is on the forefront of creating meaningful change for people.I was fascinated to learn more about the topic from Colleen, and I hope you leave this conversation with a better understanding of the gut microbiome, and some applied insights on how improving your gut health can improve your life.-----Please support our partners!We're able to keep growing and creating content for YOU because of their support. We believe in their mission and would appreciate you supporting them in return!!To take advantage of deals from our partners, head to http://www.findingmastery.net/partners where you'll find all discount links and codes mentioned in the podcast.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pacific Biosciences has introduced a new method for detecting DNA methylation simultaneously with DNA sequencing. They are calling it 5-base sequencing. Today on the program, Jonas Korlach, PacBio's Chief Scientific Officer, and Tomi Pastinen, the Director of the Genomic Medicine Center at Children's Mercy Research Institute in Kansas City join us to describe the new breakthrough and connect it to clinical possibilities.

In a genomics first, Pacific Biosciences has introduced a new method for detecting DNA methylation simultaneously with DNA sequencing. They are calling it 5-base sequencing. Today on the program, Jonas Korlach, PacBio's Chief Scientific Officer, and Tomi Pastinen, the Director of the Genomic Medicine Center at Children's Mercy Research Institute in Kansas City join us to describe the new breakthrough and connect it to clinical possibilities.

There aren't many single events that bring together a Who's Who list of the leading private and public companies in biotech and synthetic biology. The JP Morgan Healthcare Conference is one of the rare exceptions. The annual event, held every January, is one of the biggest stages for companies to reveal innovative new products in development, announce acquisitions, and form landscape-shifting collaborations. Investors were left wanting more after the 2021 meeting, which was relatively subdued due to the coronavirus pandemic. The first few days of the 2022 event seemed to live up to historical expectations, with a handful of companies making splashy announcements so far. In this episode of the podcast, 7investing Lead Advisors Simon Erickson and Maxx Chatsko sit down to provide quick takeaways on some of the biggest reveals from the beginning of the 2022 JP Morgan Healthcare Conference. These include: The unveiling of a long-read DNA sequencing technology from Illumina (NASDAQ: ILMN) and an enzymatic DNA synthesis technology from Twist Bioscience (NASDAQ: TWST). Molecular testing leader Exact Sciences (NASDAQ: EXAS) used the stage to reveal that it comfortably beat full-year 2021 guidance and jump into hereditary cancer testing. Meanwhile, Beam Therapeutics (NASDAQ: BEAM) announced a research collaboration with Pfizer (NYSE: PFE) that had an unusual structure. Simon and Maxx also share their thoughts on the slow pace of merger and acquisitions (M&A) in drug development in the last two years — and why record cash balances and a constant need for innovation at the largest companies suggest that could change in 2022. Publicly-traded companies mentioned or alluded to in this podcast include Beam Therapeutics, CRISPR Therapeutics, Eli Lilly, Exact Sciences, Illumina, Intellia Therapeutics, Novo Nordisk, Pacific Biosciences, and Twist Bioscience. 7investing's advisors may own positions in the companies that are mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education: https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing --- Send in a voice message: https://anchor.fm/7investing/message Support this podcast: https://anchor.fm/7investing/support

Learn more about your ad choices. Visit megaphone.fm/adchoices

In a joint interview, Sean George, CEO of diagnostics firm, Invitae, and Christian Henry, CEO of sequencing tools company, Pacific Biosciences, say that “it was clear in the first five minutes of a phone call that they shared a vision for doing something big together.” What comes through the interview is that this partnership is built on a big vision: speeding up the adoption of whole genome sequencing into clinical medicine as the preferred method for genetic testing.

America's health care bill may cost us $4 trillion a year. But at least we're getting more efficient. Technological advances are improving several of health care's most serious issues. Oncology diagnostics are now able to detect earlier-stage cancers before patients even begin showing symptoms. Remote monitoring is taking vital signs of the elderly without them ever needing to step into a hospital. The COVID vaccine is renewing our focus on mRNA, genomic sequencing is unlocking personalized treatments, and spatial biology is quickly capturing the full attention of the medical community. But due to heavy regulations and the specialized nature of the work, isn't the health care industry also notoriously slow to embrace innovation? Will these exciting new technology improvements actually pay off for forward-thinking investors? To help us answer those questions, we've brought in a health care expert. Nina Deka is a senior analyst for ROBO Global, where she contributes to the firm's health care technology index that carries the ticker "HTEC". Nina has spent her career either working in or covering the health care industry, and she is well-versed in the ways of how technology can improve it. In an exclusive interview, Nina spoke with 7investing CEO Simon Erickson about several of health care's most important developing trends and the specific companies that investors might consider as opportunities. Publicly-traded companies mentioned in this interview include Akoya Biosciences, Exact Sciences, Illumina, Invitae, Moderna, Pacific Biosciences of California, Teladoc, and Vocera Communications. 7investing's advisors or its guests may have positions in the companies mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education: https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing --- Send in a voice message: https://anchor.fm/7investing/message Support this podcast: https://anchor.fm/7investing/support

Despite the ability of whole genome sequencing to diagnose patients with rare genetic disease, the technology still leaves many patients without a clear diagnosis. Rady Children's Institute for Genomic Medicine, which has innovated the use of rapid whole genome sequencing in the neonatal and pediatric ICU, is now working to diagnosed patients left undiagnosed by whole genome sequencing with long-read whole genome sequencing through a collaboration with Pacific Biosciences. We spoke to Matthew Bainbridge, principal investigator and associate director of clinical genomics at Rady Children's Institute for Genomic Medicine, about the collaboration, how long-read sequencing differs from traditional whole genome sequencing, and why this is helping to find answers for undiagnosed patients with rare genetic diseases.

Genome Therapy will take the diseases out of your body and bloodline but first, you have to sequence your genome sequenced, that will be done by Illumina and Pacific Biosciences. Welcome back, tribe members! Today I'm discussing "2 More Stocks That Will Change The World Forever and Make Me a Multi-Millionaire". If you enjoy this video feel free to SUBSCRIBE! Make sure to follow me on social media for even more coverage of the stock market.The Power of a Tribe: https://www.amazon.com/dp/B096TWBDM3/...Get Surfshark VPN at  https://surfshark.deals/INVESTORS and enter promo code INVESTORS for 83% off and 3 extra months for free!  Follow Me: Facebook: https://www.facebook.com/BestofUSLLC/Instagram: https://www.instagram.com/bestofusinv...Twitter: https://twitter.com/BestOfUsInvestSubscribe:https://www.youtube.com/channel/UC-hq...Help Kerry and Nita win the race against Childhood Cancer and keep their daughter Shay's memory alive. Your support makes a direct impact in the fight against Pediatric Cancer at Children's of Alabama by helping advance research in finding a cure for cancer. http://give.childrensal.org/bestofusWe have Up-Graded Our Discord: Kerry's Portfolio, Trades and InsightsThis is the new link: https://discord.io/bestofus. It is now organized by topics and will be easier to navigate and communicate.

Biotech is offering you the investment opportunity of a lifetime.  The Healthcare Revolution is here.  Brought to you by names like Editas Intella, Beam, Crispr, Pacific Biosciences and Caribou.Welcome back, tribe members! Today I'm discussing "Biotech Stocks Will Give Me Exponential Growth The Next 5 Years and Beyond!". If you enjoy this video feel free to SUBSCRIBE! Make sure to follow me on social media for even more coverage of the stock market.The Power of a Tribe: https://www.amazon.com/dp/B096TWBDM3/...Get Surfshark VPN at  https://surfshark.deals/INVESTORS and enter promo code INVESTORS for 83% off and 3 extra months for free!  Follow Me: Facebook: https://www.facebook.com/BestofUSLLC/Instagram: https://www.instagram.com/bestofusinv...Twitter: https://twitter.com/BestOfUsInvestSubscribe:https://www.youtube.com/channel/UC-hq...Help Kerry and Nita win the race against Childhood Cancer and keep their daughter Shay's memory alive. Your support makes a direct impact in the fight against Pediatric Cancer at Children's of Alabama by helping advance research in finding a cure for cancer. http://give.childrensal.org/bestofusWe have Up-Graded Our Discord: Kerry's Portfolio, Trades and InsightsThis is the new link: https://discord.io/bestofus. It is now organized by topics and will be easier to navigate and communicate.

Colleen Cutcliffe, CEO & Co-Founder at Pendulum Therapeutics, shared the story behind her title with us on Saturday, April 10th and Sunday, April 11th, 2021.Colleen has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.SUE SAYS"As a young girl growing up in the deep south to immigrant parents, Colleen's experience was not one of racism or discrimination. She recalls the lesson she learned from her parents was that every person, no matter their background, has the absolute power to chart their own course in life. She's taken these values of integrity, hard work and education and applied them directly to her company Pendulum. "Support this podcast at — https://redcircle.com/women-to-watch-r/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Christian Henry, CEO of Pacific Biosciences, discusses hunting for Covid-19 variants. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Projects & Investigations Reporter Jason Grotto talk about "unfair" property taxes keeping black families from gaining wealth. Bloomberg Businessweek National Correspondent Josh Green discusses the story “Biden Signals Assault on Big Tech as DOJ Pick Looms.” And we Drive to the Close with Anton Schutz, President at Mendon Capital Advisors. Hosts: Carol Massar and Tim Stenovec. Producer: Doni Holloway. 

Christian Henry, CEO of Pacific Biosciences, discusses hunting for Covid-19 variants. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Projects & Investigations Reporter Jason Grotto talk about "unfair" property taxes keeping black families from gaining wealth. Bloomberg Businessweek National Correspondent Josh Green discusses the story “Biden Signals Assault on Big Tech as DOJ Pick Looms.” And we Drive to the Close with Anton Schutz, President at Mendon Capital Advisors. Hosts: Carol Massar and Tim Stenovec. Producer: Doni Holloway.  Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Colleen Cutcliffe, PhD, is co-founder and CEO of Pendulum Therapeutics, a biotech startup in San Francisco. Colleen stands alone among entrepreneurs: she is a scientist with a doctoral degree in biochemistry and molecular biology, a pioneer in the exploration of the human body’s microbiome, and a challenger of the probiotics industry and its 1970s-era formulas. Prior to Pendulum, Colleen led a team of scientists at Pacific Biosciences, a company famous for its DNA sequencing. Armed with this technology, Pendulum is doing groundbreaking microbiome research by extracting new bacterial strains, studying their impact on chronic conditions, and combining them in never-before-seen formulations. The company’s mission is to create probiotics as effective as prescription drugs, without any side effects. The company’s first offering, Pendulum Glucose Control, is the only probiotic in existence that has lowered blood sugar spikes and A1C levels in a clinical trial – welcome news for the 122 million Americans living with diabetes and prediabetes. Colleen completed her postdoctoral research at Northwestern Medicine’s Lurie Children's Hospital of Chicago. She received a doctoral degree in biochemistry and molecular biology from Johns Hopkins University and a bachelor’s degree in biochemistry from Wellesley College.  Some of the Topics Covered by Colleen Cutcliffe in this Episode What Pendulum Therapeutics is doing today and how Colleen decided to start it Why working in microbiome science is so personal for Colleen The first steps that Colleen and her co-founders took to found Pendulum The incredible journey from learning what VCs are to getting their first investment in the form of a convertible note, to finally becoming fully venture-backed The catch-22 of VCs wanting to see the milestones that you're actually fundraising in order to reach The unexpected challenges Colleen faced when asked for her bank account information Pivoting from a service company to a product business Deciding which application of their technology to focus on first Creating the product over a decade Deciding between the pharmaceutical path or going D2C How they've begun to grow their customer base The anti-drug movement and shift towards pro-natural The ongoing question of pricing a very unique product As a scientist, how Colleen approached the field of marketing Colleen's leadership style and values How Colleen recharges and creates boundaries around work The importance of having investors that are fundamentally aligned with your values Sign up for The Grind, for actionable insights and stories from successful entrepreneurs delivered to your inbox once per week: https://www.justgogrind.com/newsletter/ Listen to all episodes of the Just Go Grind Podcast: https://www.justgogrind.com/podcast/ Follow Justin Gordon on Twitter: https://twitter.com/justingordon212 Follow Justin Gordon on Instagram: https://www.instagram.com/justingordon8/

Welcome back to Investing Money With Max! In today's video I go over a new stock that I added to my portfolio. Pacific Biosciences of California, ticker PACB, is a genetics company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. The Genetics field is expected to grow at 19.5% CAGR until 2027. On top of this, some major institutions that have shown great success have invested in Pacific Biosciences. Health concerns like the pandemic have thrust public health into the spotlight and genetic companies can capitalize off of that attention. This company offers tremendous upside! Let me know what y'all think down below!

INTERNACIONAL y MERCADOS - Curiosidad de Wechat con Andorra. / Neom, la ciudad que plantean los árabes. / Hope, la misión de EUA llega a Marte con éxito. / La bolsa de NY amenaza con irse si se aprueban impuestos. // EMPRESAS - General Motors, inversiones de 27B en EV y AV. / WM Motor, chinos eléctricos. / Maker Rivian IPO / Softbank, 900M en Pacific Biosciences. / Resultados Twitter. // STARTUPS - Iroko, nigeriana, planea salir a bolsa en Londres. / Goody, startup de pre-regalos. // BLOCKCHAIN - Xend, Defi en Africa. Los enlaces de arriba en la newsletter del podcast: https://nofinancieros.substack.com/ Visita: https://nofinancieros.com/ Imagen: John French Sloan

INTERNACIONAL y MERCADOS - Curiosidad de Wechat con Andorra. / Neom, la ciudad que plantean los árabes. / Hope, la misión de EUA llega a Marte con éxito. / La bolsa de NY amenaza con irse si se aprueban impuestos. // EMPRESAS - General Motors, inversiones de 27B en EV y AV. / WM Motor, chinos eléctricos. / Maker Rivian IPO / Softbank, 900M en Pacific Biosciences. / Resultados Twitter. // STARTUPS - Iroko, nigeriana, planea salir a bolsa en Londres. / Goody, startup de pre-regalos. // BLOCKCHAIN - Xend, Defi en Africa. Los enlaces de arriba en la newsletter del podcast: https://nofinancieros.substack.com/ Visita: https://nofinancieros.com/ Imagen: John French Sloan --- Send in a voice message: https://anchor.fm/nofinancieros/message

SoftBank to invest $900 million in California gene-sequencing company Pacific Biosciences. Salesforce prepares for most employees to work remotely after the pandemic. Keith Collins hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

A TD Ameritrade report has revealed that 28% of adults ages 40 to 79 with at least $25,000 in investable assets have less than $50,000 in retirement savings. Today's stocks and topics: Vanguard Energy ETF (VDE), Pacific Biosciences of California Inc. (PACB), Seritage Growth Properties Cl A (SRG), Alliance Data Systems Corp. (ADS), Southwest Airlines Co. (LUV), ETFMG Alternative Harvest ETF (MJ), Domino's Pizza Inc. (DPZ), Boeing Co. (BA). ALSO: Universal life insurance?, from Europe-- my portfolio?, Dollar cost averaging?, Steve's talking point covers the market sectors that are likely to have good quarters. Support this podcast at — https://redcircle.com/investtalk-investment-in-stock-market-financial-planning/donations Advertising Inquiries: https://redcircle.com/brands

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.25.314252v1?rss=1 Authors: Feng, Z., Clemente, J., Wong, B., Schadt, E. Abstract: Cellular genetic heterogeneity is common in many biological conditions including cancer, microbiome, co-infection of multiple pathogens. Detecting and phasing minor variants, which is to determine whether multiple variants are from the same haplotype, play an instrumental role in deciphering cellular genetic heterogeneity, but are still difficult because of technological limitations. Recently, long-read sequencing technologies, including those by Pacific Biosciences and Oxford Nanopore, have provided an unprecedented opportunity to tackle these challenges. However, high error rates make it difficult to take full advantage of these technologies. To fill this gap, we introduce iGDA, an open-source tool that can accurately detect and phase minor single-nucleotide variants (SNVs), whose frequencies are as low as 0.2%, from raw long-read sequencing data. We also demonstrated that iGDA can accurately reconstruct haplotypes in closely-related strains of the same species (divergence [≥] 0.011%) from long-read metagenomic data. Our approach, therefore, presents a significant advance towards the complete deciphering of cellular genetic heterogeneity. Copy rights belong to original authors. Visit the link for more info

Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.

Spencer Wells was instrumental in developing many of these trends. As an Explorer-in-Residence at National Geographic, he was an early innovator of using genographic kits — studying DNA from people all across the world to map out the migrations of mankind’s earliest ancestors. Spencer went on to found a company called Insitome, which also gives consumers insight about their genome and their heritage. In an exclusive interview with 7investing, Spencer describes the permanent changes that have taken place in the Direct-to-Consumer genomics industry and explains how genomics is now catching on with hospitals. He shares his thoughts about the technology behind DNA sequencing, the personalized medicine movement in pharmaceuticals, and the importance of the ethical debate in shaping the future for gene editing. Check out https://7investing.com/subscribe to start a premium membership for $17/month and receive our 7 very best stock market ideas every month. Interview timestamps: 0:00 – Introduction: Spencer’s Indonesian Adventure 6:25 – Insitome: Changes in the Direct-to-Consumer Genomics market 11:18 – “The Disruption of Health Care”: Genetics Meets the Clinic 17:32 – An Ethical Debate: The use of Genomics and Gene Editing 23:40 – Genomic Sequencing Technology: Next-Generation Sequencing vs Nanopores 33:08 – Personalized Medicine: What will this Mean for the Drugmakers? 38:28 – National Geographic Takeaways: The Earliest Migrations of Mankind 42:26 – Spencer’s Favorite Musicians and Concerts 45:30 – What Individual Investors Should be Watching: CRISPR Publicly-traded companies mentioned in this interview include Illumina, Roche, and Pacific Biosciences. 7investing’s advisors and/or guests may have positions in the companies that are mentioned. This interview was originally recorded on May 29, 2020 and was first published on June 2, 2020. --- Send in a voice message: https://anchor.fm/7investing/message

This week on the podcast, Adam Knight of Pacific Biosciences joins us to discuss how PacBio uses ONTAP for all of its unstructured NAS workload requirements, with a focus on FlexGroup volumes!

Nicole Hynson, Associate Professor, Pacific Biosciences Research Center, the University of Hawaiʻi at Mānoa, delivers an impressive overview of the fascinating research she and her team are conducting at Hynson Lab.   Hynson heads the Hynson Lab for Community Ecology that is located in the Department of Botany at the University of Hawaiʻi at Mānoa. The lab's primary focus is the ecology of plant and fungal communities, with a particular interest in the symbiosis that exists between plants and fungi, which is known as mycorrhizae. Since 2012 her lab has been digging deep into the science of fungi. Their diverse laboratory group is comprised of advanced scientists with backgrounds in varying fields from ecology and evolution to physiology and computational biology.   Hynson details the work they do in her lab, studying the interactions fungi have with other organisms, specifically—plants. She discusses the symbiotic interactions of fungi over time. Additionally, Hynson discusses how different capacities are required to gain nutrients, detailing the function of fungi in the symbiotic relationship with plants, in which fungi assisted plants to transition from a water growth environment to soil. In exchange, the plants provided the fungi with carbon to complete their lifecycle—a truly symbiotic exchange.   The fungi expert and Ph.D. talk about the complexities of microbial symbiosis, explaining the intricate interactions that could take place between bacteria, fungi, plants, etc. As Hynson states, her job, as she sees it, is to untangle these interactions—to understand the role that they play, and how the interactions can change depending on the environmental context. Hynson says that one of her lab's goals is to use these microorganisms, specifically fungi, in restoration and conservation practices. Hynson elaborates on the other areas of great interest in regard to fungi, such as increasing crop yield, sustaining resources, and limiting the need for fertilizers.   Hynson continues with her discussion of how nutrients are transferred to hosts and how competition and diversity impact the processes. Hynson received her Ph.D. in 2010 from the University of California Berkeley and worked extensively in the Bruns Lab. And she was a vital postdoctoral researcher in the well-known lab of Prof. Kathleen Treseder at the University of California Irvine.

Why Alkermes once-promising depression drug failed to impress the FDA's advisory committee. Plus, how a $1.2 billion acquisition of Pacific Biosciences could move the needle at Illumina. Stocks: ALKS, ILMN, PACB

Just hours after Illumina announced their buyout of Pacific Biosciences, Theral sits down with longtime sequencing Omics Omics blogger, Keith Robison, and the Chief Science Officer at sequencing marketplace, AllSeq, Shawn Baker, to discuss the news which has taken the industry by surprise. A special thanks to our sponsor, Sage Science, and the quick decision on this show.

The lack of diversity in genomic data has been an issue of growing concern. It threatens to limit the benefits from the massive investment that has been made to date to transform biomedical research, drug development, and the clinical care of patients. We spoke to Jonas Korlach, chief scientific officer of Pacific Biosciences, about the problem, how it's being addressed, and the role advancing technology can play in gleaning greater insights from the genomes that are analyzed.

We sat down with John Butler, CEO of Quantumcyte who has a long history in the biotech world of Silicon Valley, specifically building tools and technology that can answer and solve complex problems effectively. Before founding Quantumcyte, John held a variety of roles in biotech companies ranging from: Applera research institute  Pacific Biosciences Applied Biosystems to being the Director of Process Development at Stanford University School of Medicine. His co-founder Dr. Bidhan Chaudhuri. The two met at Pacific Biosciences where they worked on complex products that John took from development to manufacturing and out the door.  As always Sandra and Pete deliver a great interview that makes us all wonder at what's just down the road. 

In Episode 15 of Hidden Forces, host Demetri Kofinas speaks with Dr. Eric Schadt. Eric Schadt is founder and CEO of Sema4, as well as Dean of Precision Medicine at the Icahn School of Medicine at Mount Sinai. During the course of his 20-year career, Dr. Eric Schadt has built genetics and systems biology groups at Merck. He built the computational biology group at Rosetta. He has served as co-founder of Sage Bionetworks and as Chief Science Officer of Pacific Biosciences. He now serves as the founder and CEO of Sema4. He has published more than 300 peer-reviewed papers in leading scientific journals, and he has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity and Alzheimer’s. In today’s conversation, we explore the information technology of biology – DNA – the world of genomics, where big data looms large. We begin by mapping the territory of the human genome and exploring the pathways of disease. We look to understand the ways in which complex genetic combinations express themselves as phenotypes such as height, bone structure, intelligence, and personality. How are these traits coded for? What are the instructions our body uses to repair a damaged cell? What blueprint does it consult before trying to grow new arteries? How does it know to regulate our appetite or when start us down the path of puberty? What happens when these instructions are damaged? How can the smallest difference in the order of life’s code make all the difference for our success, our happiness, and even our survival? 50 years have passed, between the discovery of the double-helix and the mapping of the first human genome. What progress have we made in the 15 years since? How has our ability to sequence new genomes created a paradigm shift in medicine? What is the role of big data and artificial intelligence in finding the correlations needed in order to treat malignancies and prevent diseases? What is the promise of genomics? What are the perils of big data in medicine? What stands between us and some superhuman future? Producer & Host: Demetri Kofinas Editor & Engineer: Stylianos Nicolaou Join the conversation on Facebook, Instagram, and Twitter at @hiddenforcespod

Researchers’ understanding of certain rare diseases is changing as new sequencing technology is providing new views of the genome. A group of diseases collectively known as repeat expansion disorders including Fragile X Syndrome, Freidrich’s Ataxia, and Huntington’s disease are being viewed in new ways thanks to the ability to read long fragments of DNA. We spoke Jonas Korlach, chief scientific officer of Pacific Biosciences, about the company’s sequencing technology, how its changing the understanding of diseases thought to be well understood, and how it may lead to improved diagnostics and therapeutics.

We’re all familiar with the announcement in the year 2000 by US President, Bill Clinton, and the UK’s Prime Minister, Tony Blair, that scientists had completed the first draft of the human genome. It was a big deal. But the actual publications didn’t happen until the next year, February of 2001. Which means that this February is the fifteenth anniversary of the publication of the first human genome. For our commemorative show we’re joined by Mike Hunkapiller, the CEO of Pacific Biosciences.

Before Bobby Sebra became the Director of Technology Development at the Icahn School of Medicine at Mt Sinai in New York he worked at Pacific Biosciences, helping to develop their single molecule, long read (SMRT) sequencing technology.

Guest: Mike Hunkapiller, CEO, Pacific Biosciences Bio and Contact Info Listen (4:58) What is the theme for 2014 at PacBio? Listen (2:50) Are you working on a clinical sequencer?

Hugh Martin, Chairman and CEO of Pacific Biosciences, looks back on the evolution of his career - from building computers to creating the future of medicine. Martin charts the lessons he learned working for large technology firms, as a leader in several successful start-ups, and while being courted by the VC community to launch a new wave in bioscience.